Surrozen Gains 7.7% Institutional Stake, Eyes FDA‑Clear Retinal Therapy & AMD Expansion
Institutional investors pile into Surrozen, backing its FDA‑cleared retinal therapy and new AMD drug. 7.7% stake boosts confidence and may drive 2027‑2029 growth.
4 minutes to read